{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:11:21Z","timestamp":1789398681657,"version":"build-2803163510"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108367","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:31:13Z","timestamp":1786033873000},"page":"108367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC"],"prefix":"10.1016","volume":"231","author":[{"given":"Xiaoxiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shize","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2026.108367_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2026.108367_bib2","unstructured":"Cancer Stat Facts: Lung and Bronchus Cancer [https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html]."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"10454","key":"10.1016\/j.phrs.2026.108367_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.phrs.2026.108367_bib5","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1200\/JCO-26-00843","article-title":"Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1","volume":"44","author":"Reuss","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.phrs.2026.108367_bib6","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1200\/JCO-26-00842","article-title":"Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1","volume":"44","author":"Bazhenova","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108367_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.phrs.2026.108367_bib8","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108367_bib9","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib10","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2026.108367_bib11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.annonc.2025.01.020","article-title":"Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors","volume":"36","author":"Riedl","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2026.108367_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.03.025","article-title":"Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF(V600E) non-small cell lung cancer","volume":"132","author":"Facchinetti","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.phrs.2026.108367_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103996","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer","volume":"9","author":"Lee","year":"2024","journal-title":"ESMO Open."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib14","article-title":"Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell. Rep. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-018-0051-4","article-title":"A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types","volume":"2","author":"Wagle","year":"2018","journal-title":"NPJ Precis. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108367_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molmed.2018.12.009","article-title":"Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology","volume":"25","author":"Sabnis","year":"2019","journal-title":"Trends Mol. Med."},{"issue":"7","key":"10.1016\/j.phrs.2026.108367_bib17","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS(G12C) Inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discov."},{"issue":"25","key":"10.1016\/j.phrs.2026.108367_bib19","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRAS(G12C) Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.phrs.2026.108367_bib20","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical Acquired Resistance to KRAS(G12C) Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"issue":"5827","key":"10.1016\/j.phrs.2026.108367_bib21","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell."},{"issue":"6","key":"10.1016\/j.phrs.2026.108367_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100319","article-title":"Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer","volume":"6","author":"Coleman","year":"2021","journal-title":"ESMO Open."},{"issue":"7377","key":"10.1016\/j.phrs.2026.108367_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108367_bib25","article-title":"BRAF Kinase Domain Duplication as a Potential On-Target Resistance Mechanism After Dabrafenib-Trametinib Therapy in a Patient With BRAF(V600E)-Mutated Lung Adenocarcinoma","volume":"9","author":"de Priester","year":"2025","journal-title":"JCO Precis. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108367_bib26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108367_bib28","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.phrs.2026.108367_bib30","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2174\/1381612033455279","article-title":"How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development","volume":"9","author":"Workman","year":"2003","journal-title":"Curr. Pharm. Des."},{"issue":"7","key":"10.1016\/j.phrs.2026.108367_bib31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"6424","key":"10.1016\/j.phrs.2026.108367_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/363045a0","article-title":"Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation","volume":"363","author":"Egan","year":"1993","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.phrs.2026.108367_bib33","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib34","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.phrs.2026.108367_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110993","article-title":"KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy","volume":"39","author":"Ryan","year":"2022","journal-title":"Cell. Rep."},{"issue":"7790","key":"10.1016\/j.phrs.2026.108367_bib37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib38","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033746","article-title":"Ras-Mediated Activation of the Raf Family Kinases","volume":"9","author":"Terrell","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"7287","key":"10.1016\/j.phrs.2026.108367_bib39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2026.108367_bib40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41591-018-0274-5","article-title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling","volume":"25","author":"Yao","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.108367_bib41","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/ncomms1727","article-title":"Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance","volume":"3","author":"Shi","year":"2012","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2026.108367_bib42","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccell.2016.06.024","article-title":"An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling","volume":"30","author":"Karoulia","year":"2016","journal-title":"Cancer Cell."},{"issue":"10","key":"10.1016\/j.phrs.2026.108367_bib43","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1158\/2159-8290.CD-12-0103","article-title":"Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors","volume":"2","author":"Ercan","year":"2012","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.phrs.2026.108367_bib44","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.phrs.2026.108367_bib45","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-09-1577","article-title":"Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)","volume":"70","author":"Dry","year":"2010","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2026.108367_bib46","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1073\/pnas.0900780106","article-title":"V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway","volume":"106","author":"Pratilas","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib47","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41467-017-00450-6","article-title":"Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer","volume":"8","author":"Jacobsen","year":"2017","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.phrs.2026.108367_bib48","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1158\/1078-0432.CCR-23-2540","article-title":"Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA\/PTEN Alterations","volume":"30","author":"Grazini","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108367_bib49","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1074\/mcp.M113.036392","article-title":"Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels","volume":"13","author":"Mertins","year":"2014","journal-title":"Mol. Cell. Proteom."},{"issue":"5","key":"10.1016\/j.phrs.2026.108367_bib50","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/labinvest.2015.37","article-title":"Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues","volume":"95","author":"G\u00fcndisch","year":"2015","journal-title":"Lab. Invest."},{"issue":"3","key":"10.1016\/j.phrs.2026.108367_bib51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00418-008-0474-z","article-title":"Immunohistochemical assessment of protein phosphorylation state: the dream and the reality","volume":"130","author":"Mandell","year":"2008","journal-title":"Histochem. Cell. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108367_bib52","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108367_bib53","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.phrs.2026.108367_bib54","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.phrs.2026.108367_bib55","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108367_bib56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2018.10.026","article-title":"Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro","volume":"126","author":"Nishino","year":"2018","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.phrs.2026.108367_bib57","first-page":"4005","article-title":"Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling","volume":"10","author":"Lin","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2026.108367_bib58","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jtho.2017.06.017","article-title":"Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance","volume":"12","author":"Wang","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108367_bib59","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jtho.2017.08.006","article-title":"Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer","volume":"12","author":"Arulananda","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"7781","key":"10.1016\/j.phrs.2026.108367_bib60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"issue":"7666","key":"10.1016\/j.phrs.2026.108367_bib62","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS","volume":"548","author":"Yao","year":"2017","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.phrs.2026.108367_bib63","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1158\/1078-0432.CCR-19-3443","article-title":"Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)","volume":"26","author":"Johnson","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108367_bib64","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2026.108367_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108038","article-title":"Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort","volume":"199","author":"Swalduz","year":"2025","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib66","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41416-023-02535-0","article-title":"Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer","volume":"130","author":"Mezquita","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.phrs.2026.108367_bib67","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108367_bib68","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2019.09.019","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study","volume":"137","author":"Mehlman","year":"2019","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2026.108367_bib69","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtho.2018.12.038","article-title":"Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers","volume":"14","author":"Vojnic","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108367_bib70","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtho.2016.11.2231","article-title":"Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib","volume":"12","author":"Ho","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108367_bib71","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.21037\/jtd-23-629","article-title":"Efficacy and tolerability of osimertinib with dabrafenib and trametinib in BRAF V600E acquired EGFR-mutant non-small cell lung cancer: a case series","volume":"16","author":"Lu","year":"2024","journal-title":"J. Thorac. Dis."},{"issue":"13","key":"10.1016\/j.phrs.2026.108367_bib72","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib73","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-021-00231-x","article-title":"Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC","volume":"5","author":"Peters","year":"2021","journal-title":"NPJ Precis. Oncol."},{"issue":"7886","key":"10.1016\/j.phrs.2026.108367_bib74","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.phrs.2026.108367_bib75","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/s41591-025-03688-6","article-title":"D3S-001 in advanced solid tumors with KRAS(G12C) mutations: a phase 1 trial","volume":"31","author":"Cho","year":"2025","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/j.phrs.2026.108367_bib76","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial","volume":"317","author":"J\u00e4nne","year":"2017","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.phrs.2026.108367_bib77","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-Class ERK1\/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.phrs.2026.108367_bib78","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-01107","article-title":"Liquid Biopsy Monitoring in BRAF V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020)","volume":"10","author":"Leonetti","year":"2026","journal-title":"JCO Precis. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108367_bib79","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib80","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis","volume":"17","author":"Planchard","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib81","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtho.2023.11.016","article-title":"Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes","volume":"19","author":"Lu","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2026.108367_bib82","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241280689","article-title":"BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer","volume":"16","author":"Lim","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"16","key":"10.1016\/j.phrs.2026.108367_bib83","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1158\/1078-0432.CCR-22-3901","article-title":"BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer","volume":"29","author":"Lim","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2026.108367_bib84","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.21037\/tlcr-24-358","article-title":"Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients","volume":"13","author":"Weng","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib85","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1038\/s41467-024-51828-2","article-title":"RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade","volume":"15","author":"Nokin","year":"2024","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.phrs.2026.108367_bib86","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/2159-8290.CD-13-0070","article-title":"Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors","volume":"3","author":"Morris","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2026.108367_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107964","article-title":"A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer","volume":"197","author":"Planchard","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phrs.2026.108367_bib88","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejca.2021.05.005","article-title":"Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers","volume":"153","author":"Schadendorf","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"31","key":"10.1016\/j.phrs.2026.108367_bib89","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase Ib\/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib90","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.phrs.2026.108367_bib91","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann. Oncol."},{"issue":"10526","key":"10.1016\/j.phrs.2026.108367_bib92","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(25)01811-2","article-title":"Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.phrs.2026.108367_bib93","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100451","article-title":"Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation","volume":"37","author":"Xiang","year":"2024","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.phrs.2026.108367_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107897","article-title":"NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China","volume":"194","author":"Zheng","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phrs.2026.108367_bib96","article-title":"Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers","volume":"2","author":"Offin","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.phrs.2026.108367_bib97","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.lungcan.2017.07.006","article-title":"Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients","volume":"111","author":"Ou","year":"2017","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib98","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jtho.2024.11.027","article-title":"Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review","volume":"20","author":"Xia","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"16","key":"10.1016\/j.phrs.2026.108367_bib99","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-22-2189","article-title":"Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers","volume":"29","author":"Rotow","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108367_bib100","article-title":"Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report","volume":"3","author":"Zhao","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"10","key":"10.1016\/j.phrs.2026.108367_bib101","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1111\/cas.13763","article-title":"Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer","volume":"109","author":"Sato","year":"2018","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib102","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12890-021-01571-x","article-title":"Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds","volume":"21","author":"Qu","year":"2021","journal-title":"BMC Pulm. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib103","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","article-title":"A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1\/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors","volume":"21","author":"Bedard","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib104","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1038\/s41467-018-07078-0","article-title":"Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors","volume":"9","author":"Fassunke","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib105","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1016\/j.cllc.2019.12.002","article-title":"Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation","volume":"21","author":"Yang","year":"2020","journal-title":"Clin. Lung Cancer"},{"issue":"12","key":"10.1016\/j.phrs.2026.108367_bib106","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/j.jtho.2019.07.018","article-title":"Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib","volume":"14","author":"Fang","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2026.108367_bib107","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-26-0704","article-title":"Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD","author":"Goldberg","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108367_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116807","article-title":"Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD","volume":"242","author":"Piotrowska","year":"2026","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib109","article-title":"Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC","volume":"4","author":"Jebbink","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib111","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108367_bib112","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jtho.2018.05.027","article-title":"Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors","volume":"13","author":"Schrock","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108367_bib113","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.phrs.2026.108367_bib114","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s43018-024-00800-6","article-title":"Co-targeting SOS1 enhances the antitumor effects of KRAS(G12C) inhibitors by addressing intrinsic and acquired resistance","volume":"5","author":"Thatikonda","year":"2024","journal-title":"Nat. Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2026.108367_bib115","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1158\/2159-8290.CD-24-0006","article-title":"D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities","volume":"14","author":"Zhang","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2026.108367_bib116","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-25-0477","article-title":"EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway","author":"Scaparone","year":"2026","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.phrs.2026.108367_bib117","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/j.cllc.2020.11.008","article-title":"Acquired Resistance to BRAF\/MEK Inhibitor Therapy in BRAF-V(600)-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations","volume":"22","author":"Metzenmacher","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.phrs.2026.108367_bib118","article-title":"The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition","volume":"6","author":"Wu","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib119","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.21037\/tlcr-20-141","article-title":"PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy","volume":"9","author":"Fang","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"19","key":"10.1016\/j.phrs.2026.108367_bib120","doi-asserted-by":"crossref","first-page":"14056","DOI":"10.1074\/jbc.M700906200","article-title":"RAS\/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation","volume":"282","author":"Roux","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.phrs.2026.108367_bib121","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/JTO.0000000000000607","article-title":"Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study","volume":"10","author":"Vansteenkiste","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108367_bib122","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jtho.2019.05.029","article-title":"SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)","volume":"14","author":"Langer","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108367_bib123","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108367_bib124","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1093\/neuonc\/noae138","article-title":"Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study","volume":"26","author":"van der Wel","year":"2024","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib125","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2026.108367_bib126","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2026.108367_bib127","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.cllc.2018.07.008","article-title":"Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor","volume":"19","author":"Helman","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108367_bib128","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtho.2020.12.011","article-title":"Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC","volume":"16","author":"Lam","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108367_bib129","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2019.11.024","article-title":"Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression","volume":"15","author":"Aldea","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"15","key":"10.1016\/j.phrs.2026.108367_bib130","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib131","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1038\/s41598-022-10288-8","article-title":"Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC","volume":"12","author":"Koyama","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108367_bib132","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.csbj.2019.09.003","article-title":"Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors","volume":"17","author":"Heydt","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"10","key":"10.1016\/j.phrs.2026.108367_bib133","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1074\/mcp.M700596-MCP200","article-title":"A portrait of tissue phosphoprotein stability in the clinical tissue procurement process","volume":"7","author":"Espina","year":"2008","journal-title":"Mol. Cell. Proteom."},{"issue":"2","key":"10.1016\/j.phrs.2026.108367_bib134","doi-asserted-by":"crossref","first-page":"522","DOI":"10.7150\/jca.26494","article-title":"First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease","volume":"10","author":"Xu","year":"2019","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib135","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-69943-7","article-title":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study","volume":"17","author":"Murciano-Goroff","year":"2026","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2026.108367_bib136","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.phrs.2026.108367_bib137","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S2213-2600(25)00258-9","article-title":"Glecirasib plus sitneprotafib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1\/2a trial","volume":"14","author":"Zhong","year":"2026","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib138","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"issue":"34","key":"10.1016\/j.phrs.2026.108367_bib139","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor-Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108367_bib140","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108367_bib141","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108367_bib142","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108367_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105807","article-title":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","volume":"10","author":"Peled","year":"2025","journal-title":"ESMO Open."},{"issue":"2","key":"10.1016\/j.phrs.2026.108367_bib144","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108367_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.109501","article-title":"Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD","volume":"218","author":"Okamoto","year":"2026","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.phrs.2026.108367_bib146","article-title":"Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 Study","volume":"6","author":"Ghafoor","year":"2025","journal-title":"JTO Clin. Res. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib147","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/cncy.22766","article-title":"Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization","volume":"132","author":"Diks","year":"2024","journal-title":"Cancer Cytopathol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108367_bib148","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2719","article-title":"Extreme loss of immunoreactive p-Akt and p-Erk1\/2 during routine fixation of primary breast cancer","volume":"12","author":"Pinhel","year":"2010","journal-title":"Breast Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2026.108367_bib149","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1158\/1078-0432.CCR-05-0422","article-title":"Stability of phosphoprotein as a biological marker of tumor signaling","volume":"11","author":"Baker","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108367_bib150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-018-0875-0","article-title":"Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing","volume":"17","author":"Guo","year":"2018","journal-title":"Mol. Cancer"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:55:25Z","timestamp":1789397725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":150,"alternative-id":["S1043661826002823"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108367","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108367"}}